Showing results (51-60 of 78) with videos related to
Sort By:
Pageof 8
Oncotarget|December 17, 2013
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic miceMarianna L Ianzano, Stefania Croci, Giordano Nicoletti, et al.International Journal of Cancer|April 22, 2003
Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12Patrizia Nanni, Giordano Nicoletti, Carla De Giovanni, et al.BMC Genomics|August 1, 2014
Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkersFederica Riccardo, Maddalena Arigoni, Genny Buson, et al.Molecular Cancer Therapeutics|April 18, 2009
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4Patrizia Nanni, Giordano Nicoletti, Arianna Palladini, et al.Cancer Research|October 7, 2010
In silico modeling and in vivo efficacy of cancer-preventive vaccinationsArianna Palladini, Giordano Nicoletti, Francesco Pappalardo, et al.Proteomics|October 20, 2010
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model systemStefania Croci, Christian V Recktenwald, Rudolf Lichtenfels, et al.Vaccine|May 12, 2009
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacyCarla De Giovanni, Giordano Nicoletti, Lorena Landuzzi, et al.Breast Cancer Research : BCR|May 23, 2015
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesisStefania Croci, Patrizia Nanni, Arianna Palladini, et al.Cancer Research|June 3, 2004
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccineCarla De Giovanni, Giordano Nicoletti, Lorena Landuzzi, et al.Molecular Biology of the Cell|January 20, 2006
CD99 acts as an oncosuppressor in osteosarcomaMaria Cristina Manara, Ghislaine Bernard, Pier-Luigi Lollini, et al.Pageof 8